Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET–CT

Immune checkpoint inhibitors (ICI) have revolutionized therapy of metastatic melanoma. The first ICI was ipilimumab, a cytotoxic T lymphocyte-associated Ag 4 (CLTA-4) inhibitor with response rates of approximately 11% and disease control of 22%. The programmed cell death 1 (PD-1) inhibitors, such as...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Immunology, Immunotherapy Immunotherapy, 2019-05, Vol.68 (5), p.813-822
1. Verfasser:	Dimitrakopoulou-Strauss, Antonia
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - therapeutic use Apoptosis Cancer Research Cell death Computed tomography Cytotoxicity Disease control Focussed Research Review Glucose Humans Immune checkpoint inhibitors Immunology Immunotherapy Immunotherapy - methods Lymphocytes T Medical imaging Medicine Medicine & Public Health Melanoma Melanoma - diagnosis Melanoma - therapy Metastases Metastasis Monitoring, Physiologic - methods Monoclonal antibodies Neoplasm Metastasis Nivolumab - therapeutic use Oncology PD-1 protein Pembrolizumab Positron emission tomography Positron Emission Tomography Computed Tomography - methods Programmed Cell Death 1 Receptor - immunology Research Design Targeted cancer therapy Tomography Tracers
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!